MarketCap
Facebook
X
Telegram
Genmab A/S Net Income | GMAB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Genmab A/S
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 7.84 B | 4.35 B | - | 4.76 B | 2.17 B | 1.47 B | 1.1 B | 1.19 B | 764 M | 301 M | 112 M | -487 M | -596 M |
Annual performance
Select metrics to display
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.84 B | -596 M | 1.91 B |
Quarterly Net Income Genmab A/S
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.41 B | 7.84 B | 1.41 B | 4.35 B | 1.36 B | - | - | 1.89 B | - | - | - | 306 M | - | - | - | 3.38 B | - | - | - | 85 M | - | - | - | 261 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.84 B | 85 M | 2.23 B |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B |  USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-89 M | - | - | $ 384 M |  Britain |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-19.4 M | - | - | $ 717 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
-381 M | $ 39.67 | 2.24 % | $ 6.35 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
-391 M | $ 8.1 | 4.59 % | $ 2.89 M | USA |
 |
Immuron Limited
IMRN
|
-5.22 M | $ 0.82 | -3.68 % | $ 189 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-48 M | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
1 M | - | - | $ 621 M | Britain |
 |
MediWound Ltd.
MDWD
|
-9.2 M | $ 14.18 | 6.38 % | $ 386 M |  Israel |
 |
Kinnate Biopharma
KNTE
|
-113 M | - | - | $ 123 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-433 M | - | - | $ 7.29 B | USA |
 |
Nektar Therapeutics
NKTR
|
-164 M | $ 37.25 | 3.04 % | $ 628 M | USA |
 |
Immunome
IMNM
|
-212 M | $ 18.71 | 4.5 % | $ 1.63 B | USA |
 |
NexImmune
NEXI
|
-32.3 M | - | 70.13 % | $ 4.12 M | USA |
 |
Kala Pharmaceuticals
KALA
|
-27 M | $ 0.16 | 2.1 % | $ 1.3 M | USA |
 |
Theravance Biopharma
TBPH
|
106 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
IMV
IMV
|
-38 M | - | - | $ 13.1 M |  Canada |
 |
Karuna Therapeutics
KRTX
|
-434 M | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-88.4 M | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-40 M | - | - | $ 229 M | USA |
|
89bio
ETNB
|
-367 M | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-94.9 M | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
-138 M | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
-67.7 M | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-43.5 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
158 K | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
3.01 M | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
-51.2 M | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
-610 M | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
-40.5 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-29.9 M | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-39.5 M | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
-24.8 M | - | - | $ 591 K |  Irlanda |
 |
Spectrum Pharmaceuticals
SPPI
|
-75.4 M | - | - | $ 189 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.2 M | - | - | $ 2.17 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-80.1 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
-223 M | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
-11.3 M | - | -8.77 % | $ 12.4 M | Israel |
 |
Histogen
HSTO
|
-10.6 M | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
-64.4 M | - | -7.23 % | $ 13 M | USA |